Genetic Signatures Limited operates as a molecular diagnostic (MDx) company in Australia, North America, Europe, the Middle East, and Africa.
Genetic Signatures Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$1.42|
|52 Week High||AU$1.04|
|52 Week Low||AU$2.13|
|1 Month Change||-13.94%|
|3 Month Change||4.80%|
|1 Year Change||-27.18%|
|3 Year Change||144.83%|
|5 Year Change||162.96%|
|Change since IPO||192.78%|
Recent News & Updates
One Genetic Signatures Limited (ASX:GSS) Analyst Just Made A Major Cut To Next Year's Estimates
One thing we could say about the covering analyst on Genetic Signatures Limited ( ASX:GSS ) - they aren't optimistic...
|GSS||AU Life Sciences||AU Market|
Return vs Industry: GSS underperformed the Australian Life Sciences industry which returned -4.8% over the past year.
Return vs Market: GSS underperformed the Australian Market which returned 20.2% over the past year.
Stable Share Price: GSS is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: GSS's weekly volatility (6%) has been stable over the past year.
About the Company
Genetic Signatures Limited operates as a molecular diagnostic (MDx) company in Australia, North America, Europe, the Middle East, and Africa. The company designs and manufactures a suite of real-time polymerase chain reaction-based products for detection of infectious diseases under EasyScreen brand name. It also provides MDx 3Base platform technology that enables hospital and pathology laboratories to screen for a range of infectious pathogens.
Genetic Signatures Fundamentals Summary
|GSS fundamental statistics|
Is GSS overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|GSS income statement (TTM)|
|Cost of Revenue||AU$11.25m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||0.012|
|Net Profit Margin||6.19%|
How did GSS perform over the long term?See historical performance and comparison
Is Genetic Signatures undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate GSS's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate GSS's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: GSS is poor value based on its PE Ratio (115.7x) compared to the Global Life Sciences industry average (46x).
PE vs Market: GSS is poor value based on its PE Ratio (115.7x) compared to the Australian market (19.8x).
Price to Earnings Growth Ratio
PEG Ratio: GSS's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: GSS is good value based on its PB Ratio (4.1x) compared to the AU Life Sciences industry average (4.9x).
How is Genetic Signatures forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GSS's earnings are forecast to decline over the next 3 years (-33.6% per year).
Earnings vs Market: GSS's earnings are forecast to decline over the next 3 years (-33.6% per year).
High Growth Earnings: GSS's earnings are forecast to decline over the next 3 years.
Revenue vs Market: GSS's revenue (0.2% per year) is forecast to grow slower than the Australian market (5.4% per year).
High Growth Revenue: GSS's revenue (0.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: GSS's Return on Equity is forecast to be low in 3 years time (0.4%).
How has Genetic Signatures performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GSS has high quality earnings.
Growing Profit Margin: GSS became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: GSS has become profitable over the past 5 years, growing earnings by 31.9% per year.
Accelerating Growth: GSS has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: GSS has become profitable in the last year, making it difficult to compare its past year earnings growth to the Life Sciences industry (59.8%).
Return on Equity
High ROE: GSS's Return on Equity (3.6%) is considered low.
How is Genetic Signatures's financial position?
Financial Position Analysis
Short Term Liabilities: GSS's short term assets (A$47.6M) exceed its short term liabilities (A$4.6M).
Long Term Liabilities: GSS's short term assets (A$47.6M) exceed its long term liabilities (A$83.0K).
Debt to Equity History and Analysis
Debt Level: GSS is debt free.
Reducing Debt: GSS has not had any debt for past 5 years.
Debt Coverage: GSS has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: GSS has no debt, therefore coverage of interest payments is not a concern.
What is Genetic Signatures's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate GSS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate GSS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if GSS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if GSS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of GSS's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dr. John R. Melki, BSc, Ph.D. has been the Chief Executive Officer of Genetic Signatures Limited since 2011 and serves as its Managing Director and also served as its Principal Advisor. Dr. Melki has been...
CEO Compensation Analysis
Compensation vs Market: John's total compensation ($USD463.71K) is about average for companies of similar size in the Australian market ($USD555.78K).
Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.
Experienced Management: GSS's management team is seasoned and experienced (7.8 years average tenure).
Experienced Board: GSS's board of directors are considered experienced (7.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Genetic Signatures Limited's employee growth, exchange listings and data sources
- Name: Genetic Signatures Limited
- Ticker: GSS
- Exchange: ASX
- Founded: 2001
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$203.117m
- Shares outstanding: 143.04m
- Website: https://www.geneticsignatures.com
- Genetic Signatures Limited
- 7 Eliza Street
- New South Wales
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/16 07:03|
|End of Day Share Price||2021/10/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.